Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
6.15
+0.27 (4.59%)
At close: Mar 6, 2026
Market Cap4.84B +303.5%
Revenue (ttm)220.66M +768.5%
Net Income-50.02M
EPS-0.06
Shares Out786.67M
PE Ration/a
Forward PE45.19
Dividendn/a
Ex-Dividend Daten/a
Volume1,575,000
Average Volume2,597,724
Open5.95
Previous Close5.88
Day's Range5.89 - 6.19
52-Week Range2.35 - 11.80
Beta0.60
RSI49.64
Earnings DateMar 10, 2026

About HKG:1167

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. Its clinical stage candidates include Glecirasib (JAB-21822), a KRAS G12C inhibitor under various stage studies for indications, such as NSCLC, PDAC, CRC, and other solid tumors; Sitneprotafib (JAB-3312), an SHP2 inhibitor that is in Phase III trials for NSCLC indication; JAB-23E73, a Pan-KRAS inhibitor for indications, including PDAC, CRC, and NSCLC; JAB-2485 Aurora A inhibitor, JAB-30355 p53 Y220C re... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 211
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1167
Full Company Profile

Financial Performance

In 2024, HKG:1167's revenue was 155.71 million, an increase of 145.13% compared to the previous year's 63.52 million. Losses were -155.71 million, -56.64% less than in 2023.

Financial numbers in CNY Financial Statements